Skip to content
TrialScanner

NCT04467905

ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2

Phase 2CompletedMISTLead

Registry record

Lead sponsor
Milestone Pharmaceuticals Inc.
Conditions
Atrial Fibrillation
Primary completion
Aug 3, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04467905 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04467905: ReVeRA-201: Etripamil in... | TrialScanner